Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro - Takeaways - MDSpire

Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro

  • By

  • Manoj S Nair

  • Maria I Luck

  • Yaoxing Huang

  • Yosef Sabo

  • David D Ho

  • August 12, 2024

  • 0 min

Share

  • 1

    Infectious SARS-CoV-2 persistence was documented in vitro following treatment with nirmatrelvir, a 3CL protease inhibitor.

  • 2

    Viral rebound occurs in approximately 20% of COVID-19 patients treated with nirmatrelvir, despite initial symptom improvement.

  • 3

    The half-life of infectious SARS-CoV-2 was approximately 1 day, suggesting it could outlast the treatment duration.

  • 4

    Extending nirmatrelvir treatment beyond 8 days eliminated viral rebound in vitro, indicating a potential clinical strategy.

  • 5

    The study rules out drug resistance, reinfection, and inadequate immune responses as causes for viral rebound.

Original Source(s)

Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro

  • by Manoj S Nair, Maria I Luck, Yaoxing Huang, Yosef Sabo, David D Ho

  • August 12, 2024

Related Content

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

SARS-CoV-2 and reproductive system: a scientometric study

Characterization of post-COVID syndrome by self-perceived symptom severity stratified by infection wave: beyond COVID, a prospective, multicenter cohort study in Germany